These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584 [TBL] [Abstract][Full Text] [Related]
48. Are MuSK antibodies the primary cause of myasthenic symptoms? Selcen D; Fukuda T; Shen XM; Engel AG Neurology; 2004 Jun; 62(11):1945-50. PubMed ID: 15184594 [TBL] [Abstract][Full Text] [Related]
49. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Punga AR; Flink R; Askmark H; Stålberg EV Muscle Nerve; 2006 Jul; 34(1):111-5. PubMed ID: 16453324 [TBL] [Abstract][Full Text] [Related]
50. The features of myasthenia gravis with autoantibodies to MuSK. Lavrnic D; Losen M; Vujic A; De Baets M; Hajdukovic LJ; Stojanovic V; Trikic R; Djukic P; Apostolski S J Neurol Neurosurg Psychiatry; 2005 Aug; 76(8):1099-102. PubMed ID: 16024887 [TBL] [Abstract][Full Text] [Related]
51. Single-fiber electromyography during menstrual exacerbation and ovulatory suppression in MuSK antibody-positive myasthenia gravis. Stickler DE; Stickler LL Muscle Nerve; 2007 Jun; 35(6):808-11. PubMed ID: 17221882 [TBL] [Abstract][Full Text] [Related]
52. Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status. Usmani A; Kwan L; Wahib-Khalil D; Trivedi J; Nations S; Sarode R J Clin Apher; 2019 Aug; 34(4):416-422. PubMed ID: 30779438 [TBL] [Abstract][Full Text] [Related]
54. Myopathic changes detected by quantitative electromyography in patients with MuSK and AChR positive myasthenia gravis. Nikolic A; Basta I; Stojanovic VR; Stevic Z; Peric S; Lavrnic D J Clin Neurosci; 2016 May; 27():126-9. PubMed ID: 26778359 [TBL] [Abstract][Full Text] [Related]
55. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis. Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A Front Immunol; 2020; 11():613. PubMed ID: 32431692 [TBL] [Abstract][Full Text] [Related]
56. The high frequency and clinical feature of seronegative myasthenia gravis in Southern China. Feng HY; Wang HY; Liu WB; He XT; Huang X; Luo CM; Li Y Neurol Sci; 2013 Jun; 34(6):919-24. PubMed ID: 22829131 [TBL] [Abstract][Full Text] [Related]
57. Cholinergic hyperactivity in patients with myasthenia gravis with MuSK antibodies: A neurophysiological study. Modoni A; Mastrorosa A; Spagni G; Evoli A Clin Neurophysiol; 2021 Aug; 132(8):1845-1849. PubMed ID: 34147009 [TBL] [Abstract][Full Text] [Related]
58. AChR myasthenia gravis switching to MuSK or double antibody positive myasthenia gravis in two children and literature review. Lu Y; Ran H; Yang W; Ma Q; Qiu L; Ou C; Chen P; Lin Z; Liu W Neuromuscul Disord; 2020 Jul; 30(7):534-538. PubMed ID: 32387283 [TBL] [Abstract][Full Text] [Related]
59. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Leite MI; Jacob S; Viegas S; Cossins J; Clover L; Morgan BP; Beeson D; Willcox N; Vincent A Brain; 2008 Jul; 131(Pt 7):1940-52. PubMed ID: 18515870 [TBL] [Abstract][Full Text] [Related]
60. Myasthenia gravis experimentally induced with muscle-specific kinase. Shigemoto K; Kubo S; Jie C; Hato N; Abe Y; Ueda N; Kobayashi N; Kameda K; Mominoki K; Miyazawa A; Ishigami A; Matsuda S; Maruyama N Ann N Y Acad Sci; 2008; 1132():93-8. PubMed ID: 18096854 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]